glimepiride has been researched along with Atherosclerosis in 12 studies
glimepiride: structure given in first source
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
Excerpt | Relevance | Reference |
---|---|---|
" This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 9.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
"To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes." | 9.13 | Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. ( De Larochellière, R; Hu, B; Jure, H; Kupfer, S; Lincoff, AM; Mavromatis, K; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Saw, J; Staniloae, CS; Tuzcu, EM; Wolski, K, 2008) |
"Glimepiride appears to improve insulin resistance and atherosclerotic disorders." | 9.12 | Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006) |
"The purpose of this study was to examine the potential prophylactic effect of glimepiride on experimental atherosclerosis in rabbits and to elucidate the mechanism of action." | 7.73 | Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. ( Oshima, K; Shakuto, S; Tsuchiya, E, 2005) |
" This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 5.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
"To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes." | 5.13 | Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. ( De Larochellière, R; Hu, B; Jure, H; Kupfer, S; Lincoff, AM; Mavromatis, K; Nesto, R; Nicholls, SJ; Nissen, SE; Perez, A; Saw, J; Staniloae, CS; Tuzcu, EM; Wolski, K, 2008) |
"Glimepiride appears to improve insulin resistance and atherosclerotic disorders." | 5.12 | Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006) |
"The purpose of this study was to examine the potential prophylactic effect of glimepiride on experimental atherosclerosis in rabbits and to elucidate the mechanism of action." | 3.73 | Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. ( Oshima, K; Shakuto, S; Tsuchiya, E, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (83.33) | 29.6817 |
2010's | 1 (8.33) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
Authors | Studies |
---|---|
Werida, R | 1 |
Kabel, M | 1 |
Omran, G | 1 |
Shokry, A | 1 |
Mostafa, T | 1 |
Shah, R | 1 |
Fresco, C | 1 |
Tawakol, A | 1 |
Finn, AV | 1 |
Yang, B | 1 |
Tian, H | 1 |
Ren, Y | 1 |
Tong, N | 1 |
Yu, H | 1 |
Han, L | 1 |
Ran, X | 1 |
Forst, T | 1 |
Hohberg, C | 1 |
Fuellert, SD | 1 |
Lübben, G | 1 |
Konrad, T | 1 |
Löbig, M | 1 |
Weber, MM | 1 |
Sachara, C | 1 |
Gottschall, V | 1 |
Pfützner, A | 1 |
Shakuto, S | 1 |
Oshima, K | 1 |
Tsuchiya, E | 1 |
Koshiba, K | 1 |
Nomura, M | 1 |
Nakaya, Y | 1 |
Ito, S | 1 |
Giugliano, D | 1 |
Esposito, K | 1 |
Kida, Y | 1 |
Sato, T | 1 |
Steg, PG | 1 |
Marre, M | 1 |
Nissen, SE | 1 |
Nicholls, SJ | 1 |
Wolski, K | 1 |
Nesto, R | 1 |
Kupfer, S | 1 |
Perez, A | 1 |
Jure, H | 1 |
De Larochellière, R | 1 |
Staniloae, CS | 1 |
Mavromatis, K | 1 |
Saw, J | 1 |
Hu, B | 1 |
Lincoff, AM | 1 |
Tuzcu, EM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560] | Phase 4 | 80 participants (Actual) | Interventional | 2018-10-08 | Completed | ||
A Double-Blind, Randomized, Comparator-Controlled Study In Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultr[NCT00225277] | Phase 3 | 547 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Due to low event rates, number of subjects experiencing any of the composite endpoint A cardiovascular events is being reported instead of time to first occurrence. Endpoint A conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
Intervention | Participants (Number) |
---|---|
Pioglitazone QD | 5 |
Glimepiride QD | 6 |
Due to low event rates, number of subjects experiencing any of the composite endpoint B cardiovascular events is being reported instead of time to first occurrence. Endpoint B conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
Intervention | Participants (Number) |
---|---|
Pioglitazone QD | 40 |
Glimepiride QD | 41 |
Due to low event rates, number of subjects experiencing any of the composite endpoint C cardiovascular events is being reported instead of time to first occurrence. Endpoint C conditions listed in Limitations and Caveats section. (NCT00225277)
Timeframe: Up to 72 weeks
Intervention | participants (Number) |
---|---|
Pioglitazone QD | 11 |
Glimepiride QD | 13 |
The nominal change in normalized total atheroma volume as measured by the average of plaque areas for all slices of anatomically comparable segments of the target coronary artery multiplied by the mean number of matched slices in the population. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)
Intervention | Percent volume (Least Squares Mean) | |
---|---|---|
Baseline | Nominal Change from Baseline | |
Glimepiride QD | 217.619 | -1.480 |
Pioglitazone QD | 206.579 | -5.528 |
The nominal change from baseline in percent atheroma volume for all slices of anatomically comparable segments of the target coronary artery. Assessment completed at the Week 72 visit or Final Visit if treatment was prematurely discontinued. (NCT00225277)
Timeframe: Baseline and Final Visit (up to 72 weeks)
Intervention | Percent volume (Least Squares Mean) | |
---|---|---|
Baseline | Nominal Change from Baseline | |
Glimepiride QD | 40.016 | 0.725 |
Pioglitazone QD | 40.592 | -0.161 |
The incidence of cardiovascular events and composite endpoints occurring within 30 days of last dose as adjudicated by the Clinical Endpoint Committee. Abbreviations: PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; CHF: Congestive Heart Failure. (NCT00225277)
Timeframe: Up to 72 weeks
Intervention | Number of Events (Number) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nonfatal Myocardial Infarction | Nonfatal Stroke | Coronary Revascularization: PCI/CABG counted once | Coronary Revascularization: PCI | Coronary Revascularization: CABG | Carotid Endarterectomy/Stenting | Hospitalization for Unstable Angina | CHF Hospitalization: new/exacerbated counted once | Hospitalization for New CHF | Hospitalization for Exacerbated CHF | Noncardiovascular Mortality | Cardiovascular Mortality | Composite Endpoint A | Composite Endpoint B | Composite Endpoint C | |
Glimepiride QD | 4 | 1 | 30 | 28 | 2 | 0 | 2 | 5 | 2 | 3 | 1 | 1 | 6 | 41 | 13 |
Pioglitazone QD | 2 | 0 | 29 | 25 | 5 | 1 | 4 | 4 | 4 | 0 | 0 | 3 | 5 | 40 | 11 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
Intervention | mmol/l (Mean) | |
---|---|---|
Baseline FSG | 3rd Month FSG | |
Metformin ( 002 Group) | 6.2 | 6.5 |
Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
Intervention | μU/ml (Mean) | |
---|---|---|
Baseline FSI | 3rd month FSI | |
Metformin ( 002 Group) | 13.0 | 13.9 |
Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
Intervention | percentage (Mean) | |
---|---|---|
Baseline HbA1c | 3rd month HbA1c | |
Metformin ( 002 Group) | 7.8 | 7.0 |
Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
Intervention | percentage (Mean) | |||
---|---|---|---|---|
Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
Intervention | Score on a scale ( SI unit) (Mean) | |||
---|---|---|---|---|
Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
Intervention | mg/dl (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
4 trials available for glimepiride and Atherosclerosis
Article | Year |
---|---|
Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.
Topics: Adiponectin; Atherosclerosis; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, | 2020 |
Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.
Topics: Aged; Atherosclerosis; Biomarkers; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Humans; Hypo | 2005 |
Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis.
Topics: Adipocytes; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; | 2006 |
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum | 2008 |
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum | 2008 |
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum | 2008 |
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Vessels; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hum | 2008 |
8 other studies available for glimepiride and Atherosclerosis
Article | Year |
---|---|
Pioglitazone vs glimepiride in the PERISCOPE trial.
Topics: Atherosclerosis; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; H | 2008 |
Pioglitazone vs glimepiride in the PERISCOPE trial.
Topics: Atherosclerosis; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-C | 2008 |
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art | 2011 |
[The change of atherogenic index of plasma (AIP) level in type 2 diabetic pedigrees and the response of AIP to Acarbose or Glimepiride in therapy of type 2 diabetes mellitus].
Topics: Acarbose; Atherosclerosis; Body Mass Index; Case-Control Studies; Cholesterol, HDL; Diabetes Mellitu | 2005 |
Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Aorta; Atherosclerosis; Cells, Cultured; Cholesterol, Dietary; Copper; Coronary Vessels; En | 2005 |
Pioglitazone vs glimepiride and carotid intima-media thickness.
Topics: Atherosclerosis; Carotid Arteries; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglyce | 2007 |
Pioglitazone vs glimepiride and carotid intima-media thickness.
Topics: Albuminuria; Atherosclerosis; Carotid Arteries; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Huma | 2007 |
Does PERISCOPE provide a new perspective on diabetic treatment?
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Sulfonylurea | 2008 |